In8bio Inc (INAB) 13F Filing Data & Analysis (Q2 2026)

INAB ranks #8281 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

21 institutions disclose a position in INAB, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 1.1% of its own portfolio to it.

Stonepine Capital Management, LLC has added to its INAB position for two straight quarters, increasing it by $1.9M to reach $2.3M today.

Alyeska Investment Group, L.P. has trimmed its INAB position for two straight quarters, cutting it by $899.7K while still holding $1.3M.

INAB is up 1.3% today, and institutions have been net buyers of $1.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

INAB reported a net loss of $19.4M in its latest fiscal year.

• Not yet profitable — net loss of $19.4M in the latest fiscal year
• Net income improved year over year, from -$30.4M to -$19.4M
• Operating cash flow was negative, using $12.7M in cash
• Current ratio of 8.82x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.17x equity — within a conventional range